Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CINGW
Upturn stock ratingUpturn stock rating

Cingulate Inc. Warrants (CINGW)

Upturn stock ratingUpturn stock rating
$0.05
Last Close (24-hour delay)
Profit since last BUY-37.5%
upturn advisory
WEAK BUY
BUY since 7 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CINGW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.05
high$

Analysis of Past Performance

Type Stock
Historic Profit -82.14%
Avg. Invested days 20
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.86
52 Weeks Range 0.01 - 0.18
Updated Date 06/19/2025
52 Weeks Range 0.01 - 0.18
Updated Date 06/19/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.73

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -114.14%
Return on Equity (TTM) -358.06%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 4237731
Shares Outstanding -
Shares Floating 4237731
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cingulate Inc. Warrants

stock logo

Company Overview

overview logo History and Background

Cingulate Inc. is a biopharmaceutical company focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD). The warrants represent the right to purchase shares of Cingulate's common stock at a specified price and time.

business area logo Core Business Areas

  • Pharmaceutical Development: Focused on developing and commercializing novel therapies for ADHD.

leadership logo Leadership and Structure

Details about Cingulate's leadership team and organizational structure are publicly available via their investor relations website and SEC filings.

Top Products and Market Share

overview logo Key Offerings

  • CTX-1301: CTX-1301 is Cingulate's lead product candidate, an oral immediate-release formulation of dexmethylphenidate. Market share data is not yet applicable as the product is still under development. Competitors include other ADHD medications like Adderall and Ritalin.
  • CTX-1302: CTX-1302 is Cingulate's other leading product candidate, focusing on extended release ADHD medication. Market share data is not applicable as it is under development. Competitors include Concerta and Vyvanse.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry focused on ADHD treatments is characterized by significant demand and ongoing research and development.

Positioning

Cingulate aims to differentiate itself through innovative formulations with potential for improved efficacy and safety profiles.

Total Addressable Market (TAM)

The ADHD treatment market is estimated to be in the billions of dollars. Cingulate is positioned to capture a portion of this TAM with successful product launches.

Upturn SWOT Analysis

Strengths

  • Novel product candidates
  • Experienced management team
  • Focus on unmet needs in ADHD treatment

Weaknesses

  • Limited financial resources
  • Reliance on clinical trial success
  • Competition from established pharmaceutical companies

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new ADHD-related indications

Threats

  • Regulatory hurdles
  • Clinical trial failures
  • Generic competition

Competitors and Market Share

competitor logo Key Competitors

  • TEVA
  • ALKS
  • SHPG

Competitive Landscape

Cingulate faces intense competition from established pharmaceutical companies with larger resources and existing ADHD treatments. Cingulate needs FDA approval and successful clinical trial results to compete.

Growth Trajectory and Initiatives

Historical Growth: N/A (Development-stage company)

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals.

Recent Initiatives: Recent initiatives include advancing CTX-1301 and CTX-1302 through clinical trials.

Summary

Cingulate Inc. Warrants represent a speculative investment tied to the success of Cingulate's ADHD drug development program. As a development-stage company, Cingulate is dependent on securing funding and the successful completion of clinical trials. Positive clinical trial results and subsequent FDA approval would create substantial shareholder value. However, regulatory hurdles and clinical trial failures could significantly impact Cingulate's prospects. Investors should carefully consider the risks associated with investing in development-stage pharmaceutical companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Financial News Outlets

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cingulate Inc. Warrants

Exchange NASDAQ
Headquaters Kansas City, KS, United States
IPO Launch date 2021-12-08
Co-Founder, CEO & Chairman of the Board Dr. Shane J. Schaffer Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.